SACHLARD FILM COATED TABLETS 500MG

XL LABORATORIES PRIVATE LIMITED (INDIA)🇸🇬 Health Sciences Authority

Approval Date: Oct 2, 2025
Approval ID: 343d153e25d144de
Company: XL LABORATORIES PRIVATE LIMITED (INDIA)
Type: Therapeutic

Approval Details

Approval Id: 343d153e25d144de
Drug Name: SACHLARD FILM COATED TABLETS 500MG
Product Name: SACHLARD FILM COATED TABLETS 500MG
Approval Number: SIN17347P
Approval Date: 2025-10-02
Registrant: GOLDPLUS UNIVERSAL PTE LTD
Licence Holder: GOLDPLUS UNIVERSAL PTE LTD
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET, FILM COATED
Dosage: DOSAGE AND ADMINISTRATION The usual dose of Levofloxacin Tablets is 500 mg administered orally, as indicated by infection and described in the following dosing chart. These recommendations apply to patients with normal renal function (i.e., creatinine clearance > 80 mL/min). For patients with altered renal function see the Patients with Impaired Renal Function subsection – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Oral doses should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine, chewable/buffered tablets or the paediatric powder for oral solution <img src="/TGIF/Sachlard-Table1.png" alt="Sachlard Dosage Table 1" /> <img src="/TGIF/Sachlard-Table2.png" alt="Sachlard Dosage Table 2" /> When only the serum creatinine is known, the following formula may be used to estimate creatinine clearance. <img src="/TGIF/Sachlard-Formula1.png" alt="Sachlard Dosage Formula 1" /> The serum creatinine should represent a steady state of renal function.
Route Of Administration: ORAL
Indication Info: INDICATIONS AND USAGE Levofloxacin Tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis. Acute bacterial exacerbation of chronic bronchitis due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. Community-acquired pneumonia due to Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-resistant strains, MIC value for penicillin ≥2mcg/mL), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae. (See CLINICAL STUDIES – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.) Nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended. Complicated skin and skin structure infections due to methicillin-sensitive Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis. Uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections due to Staphylococcus aureus, or Streptococcus pyogenes. Complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Acute pyelonephritis (mild to moderate) caused by Escherichia coli. Uncomplicated urinary tract Infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.
Contraindications: CONTRAINDICATIONS Levofloxacin is contraindicated in persons with a history of hypersensitivity to levofloxacin, quinolone antimicrobial agents, or any other components of this product.

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Oct 2, 2025

Approval ID

343d153e25d144de

Type

Therapeutic

Back to HSA Approvals